Asenapine Maleate

马来酸阿塞那平

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameAsenapine Maleate
Drug Alias Name马来酸氯氧平Asenapinum阿塞纳平阿塞那平Sycrest +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderSchizophrenia, ParanoidSchizophrenia, Disorganized +[7] 
Global Approved IndicationsSchizophreniaBipolar Disorder
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/08/13
Country/TerritoryBulgariaUnited StatesUkraine +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMeiji Seika PharmaAbbvie IncN.V. Organon +[4] 
Inactive CompaniesUniversity of California IrvineSun Pharmaceutical Industries LtdNoven Pharmaceuticals Inc +[8] 
Active IndicationsSchizophreniaBipolar Disorder
Inactive IndicationsBipolar I DisorderSchizophrenia, ParanoidSchizophrenia, Disorganized +[5] 

Other Information

ATC CodeN05AH05
Related LinksWikipediaDrugBankKEGG